Core Insights - The Beijing Stock Exchange (BSE) is celebrating its fourth anniversary, having established itself as a key player in the multi-tiered capital market, focusing on serving innovative small and medium-sized enterprises (SMEs) [1][11] Market Growth - Over the past four years, the BSE has seen significant growth, with 282 listed companies and a total market capitalization exceeding 900 billion yuan, approaching the 1 trillion yuan mark [1][3] - As of November 13, 2023, the total market capitalization of listed companies on the BSE is approximately 912.58 billion yuan [3] - The number of listed companies has increased from 123 in 2022 to 282 in 2023, with 25 new listings in the fourth anniversary year [3] Company Performance - Among the listed companies, Beiterui leads with a market capitalization of 41.85 billion yuan, followed by Jinbo Biological at 27.42 billion yuan [3] - Jinbo Biological's stock price reached 238.31 yuan per share, marking it as one of the top-performing stocks [4][5] - The average revenue for BSE companies in the third quarter was 520 million yuan, reflecting a year-on-year growth of 6%, with 230 companies reporting profits [6][7] IPO Pipeline - Currently, there are 170 companies in the IPO pipeline for the BSE, indicating a robust interest in listing [8] - The IPO review process has accelerated, with multiple companies receiving approvals in recent weeks [9][10] Policy Support - The China Securities Regulatory Commission (CSRC) emphasizes the importance of the BSE in supporting innovative SMEs and plans to enhance its development [11][12] - The BSE has implemented various policies to improve market functionality and attract quality enterprises, including the introduction of the North Certificate Specialized Index [12] Investor Engagement - More than 90% of listed companies on the BSE have engaged in dividend distribution, with nearly 9.5 million qualified investors participating in the market [14]

山西锦波生物医药股份有限公司 关于召开 2025 年第三季度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 山西锦波生物医药股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日在北京证券交易所官网（www.bse.cn）披露了《2025 年第三季度报告》（公告 编号：2025-170），为方便广大投资者更深入了解公司 2025 年第三季度经营业绩 的具体情况，加强与投资者的交流互动，公司拟召开 2025 年第三季度报告业绩 说明会。 证券代码：920982 证券简称：锦波生物 公告编号：2025-180 本次说明会采用网络方式召开。 为充分尊重投资者、提升交流的针对性，现就公司本次业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2025 年 11 月 19 日(星期三)10:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入 问题征集专题页面。公司将在业绩说明会上，对投资者普遍关注的问题 ...

Core Insights - The medical beauty sector experienced a 1.15% increase on November 13, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Medical Beauty Sector Performance - *ST Meigu (000615) closed at 4.77, with a rise of 5.07% and a trading volume of 105,700 shares, amounting to a transaction value of 50.0584 million yuan [1] - Jinbo Biological (920982) closed at 238.31, up 2.24%, with a trading volume of 11,200 shares and a transaction value of 268 million yuan [1] - Aimeike (300896) closed at 159.60, up 1.22%, with a trading volume of 33,700 shares and a transaction value of 534 million yuan [1] - Huaxi Biological (688363) closed at 51.77, up 0.52%, with a trading volume of 19,300 shares and a transaction value of 9.9559 million yuan [1] Fund Flow Analysis - The medical beauty sector saw a net outflow of 48.455 million yuan from institutional investors, while retail investors contributed a net inflow of 20.9995 million yuan [1] - Specific fund flows for key companies include: - *ST Meigu: Institutional net outflow of 384,800 yuan, retail net inflow of 113,790 yuan [2] - Huaxi Biological: Institutional net outflow of 15.0817 million yuan, retail net inflow of 13.8661 million yuan [2] - Aimeike: Institutional net outflow of 32.9885 million yuan, retail net inflow of 599,550 yuan [2]

Core Insights - The article emphasizes the significant role of the Beijing Stock Exchange (BSE) in empowering innovative small and medium-sized enterprises (SMEs) amidst a backdrop of policy benefits and accelerated innovation [1] - The BSE has become a core window for observing the growth of Chinese SMEs and the deepening of capital market reforms, with nearly 950,000 qualified investors and various institutional funds creating a diverse ecosystem [1] Investment Opportunities - The BSE 50 Index, consisting of 50 representative stocks, is highlighted as a key investment direction, providing precise coverage of innovative SMEs and including many "hidden champions" in niche markets [1][4] - As of mid-2025, 40% of the BSE 50 constituents are specialized and innovative enterprises, and 88% are high-tech companies, indicating a strong focus on growth potential [1] Performance Metrics - The BSE 50 Index has shown a nearly 50% increase in 2025, outperforming major A-share indices and attracting significant investor attention [4][6] - The trading volume of the BSE 50 Index reached 44 times that of its initial establishment in 2022, indicating a substantial increase in liquidity [3][11] Policy Support - Continuous policy support is identified as a core driving force behind the BSE 50 Index's strength, with various reforms aimed at enhancing market ecology and efficiency [7] - The introduction of a new ETF for the BSE 50 is expected to inject over 20 billion yuan into the market, boosting investor confidence [7] Sector Focus - The BSE 50 Index primarily invests in strategic emerging industries such as power equipment, machinery, and electronics, which are crucial for traditional industry transformation and economic growth [8] - The focus on "hard tech" sectors like AI and renewable energy is expected to unlock growth potential in response to policy and market demand [8] Institutional Participation - Institutional funds have accelerated their investment in the BSE, with public funds holding over 10 billion yuan in BSE market capitalization by the end of Q3 2025, reflecting a significant year-on-year increase [9] - The diverse ecosystem formed by nearly 950,000 qualified investors and institutional funds has significantly enhanced market liquidity [9] Investment Strategies - The article discusses the introduction of the Zhongjia BSE 50 Enhanced Index Fund, which aims to balance risk and return through a dual strategy of passive tracking and active enhancement [17] - The fund employs a quantitative model that combines human expertise and AI to optimize stock selection and reduce volatility, catering to both conservative and aggressive investors [18][20]

Core Points - As of November 12, the total margin financing and securities lending balance on the Beijing Stock Exchange (BSE) is 7.844 billion yuan, a decrease of 54.58 million yuan from the previous trading day, marking a continuous decline for seven consecutive trading days [1] - The stocks with the highest margin financing balances include Jinbo Biological, Shuguang Digital Innovation, and Better Energy, with latest financing balances of 408 million yuan, 335 million yuan, and 297 million yuan respectively [1] - A total of 106 stocks on the BSE received net margin purchases on November 12, with 21 stocks having net purchases exceeding 1 million yuan, led by Litong Technology with a net purchase of 10.0662 million yuan [1][2] Industry Analysis - The industries with the most stocks receiving net margin purchases over 1 million yuan include machinery equipment, electric power equipment, and basic chemicals, with 7, 4, and 2 stocks respectively [2] - On November 12, the average decline for stocks with net margin purchases exceeding 1 million yuan was 0.65%, with the top gainers being Sanyuan Gene, Beiyikang, and Zhongfang Biao, which increased by 12.45%, 4.08%, and 4.02% respectively [2] - The average turnover rate for stocks with net margin purchases exceeding 1 million yuan on November 12 was 4.74%, with the highest turnover rates recorded for Rongyi Precision, Jinhua New Materials, and Xin Ganjiang at 16.26%, 14.42%, and 13.73% respectively [2] Stock Performance - The stocks with the highest increases in margin financing balances on November 12 include Litong Technology, Sanyuan Gene, and Lingge Technology, with increases of 10.0662 million yuan, 9.4553 million yuan, and 6.6036 million yuan respectively [3][4] - The stock with the highest margin financing balance on November 12 was Litong Technology, which had a balance of 115.58 million yuan despite a decline of 6.88% in its stock price [3] - Other notable stocks with significant margin financing increases include Tongli Co., Liancheng CNC, and Gebijia, with respective increases of 6.1667 million yuan, 5.9608 million yuan, and 5.3861 million yuan [3][4]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Views - The company reported a revenue of 1.296 billion yuan for Q1-Q3 2025, representing a year-on-year growth of 31.10%. The net profit attributable to the parent company was 568 million yuan, up 9.29% year-on-year. However, in Q3 alone, revenue was 437 million yuan, showing a growth of 13.36%, while net profit decreased by 16.24% year-on-year [2][4][11] - The revenue growth in the first three quarters was primarily driven by the sales of Class III medical devices and functional skincare products, particularly the implant products based on recombinant human collagen and the growth of the company's proprietary brand [11] - The company is expected to see a recovery in performance with the upcoming launch of new products, particularly the small-sized gel product WeaveCOL, which is anticipated to enhance market acceptance and circulation [11] Summary by Sections Financial Performance - For Q1-Q3 2025, the company achieved a revenue of 1.296 billion yuan, a 31.10% increase year-on-year, and a net profit of 568 million yuan, a 9.29% increase year-on-year. In Q3 alone, revenue was 437 million yuan, a 13.36% increase, while net profit fell by 16.24% year-on-year [2][4] - The gross profit margin decreased by 1.6 percentage points to 90.8%, and the net profit margin dropped by 8.7 percentage points to 43.9% due to increased sales, management, R&D, and financial expenses [11] Product Development - The company launched a new product, WeaveCOL, which is a small-sized gel targeting the periorbital area. This product is expected to have better market acceptance due to its smaller size and precise targeting compared to previous products [11] Future Outlook - The company is projected to have an EPS of 1.53, 2.35, and 2.60 yuan per share for the years 2025, 2026, and 2027 respectively, indicating a positive growth trajectory [11]

Core Insights - The collagen market is experiencing a downturn, with major brands like Kefu Mei and Juzhi Biotech showing a decline in growth and sales performance [1][5][6] - The market is undergoing a transformation, moving from a focus on consumer beauty products to medical applications, as companies adapt to changing consumer demands and competitive pressures [9][12][13] Market Performance - Kefu Mei's GMV on Douyin dropped to 0.5-0.75 billion yuan from over 1 billion yuan year-on-year [5] - Juzhi Biotech's stock price has fallen by 55.18% since reaching a peak of 85.14 HKD on May 20, 2023 [6][7] - The overall sales performance of collagen brands during the 2025 Double Eleven shopping festival was disappointing compared to previous years [5] Strategic Shifts - Juzhi Biotech is expanding into the B2B market by obtaining medical device registration for a collagen-based product, indicating a strategic shift towards medical applications [7][12] - Companies are increasingly focusing on technological advancements and clinical applications rather than just marketing and branding [10][13] Industry Trends - The collagen industry is moving away from purely cosmetic applications towards medical uses, with a focus on proving efficacy through clinical trials and regulatory approvals [9][12][13] - The competitive landscape is evolving, with companies needing to demonstrate the scientific validity of their products to gain market share [12][13] Innovation and Development - Huaxi Biotech is actively pursuing new patents related to collagen, indicating ongoing investment in research and development [10][11] - Companies like Furuida and Mianmei are also advancing in the medical device space, with new certifications and product developments aimed at surgical applications [12][13]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [1] Core Viewpoints - The Ministry of Finance continues to implement measures to boost consumption, including providing financial subsidies for personal consumption loans and encouraging private investment [5] - The Consumer Price Index (CPI) showed a year-on-year increase of 0.2% in October 2025, indicating effective policies to expand domestic demand [5] - The demand for trendy toys is rapidly growing, driven by Generation Z and emotional value, with AI technology integration expected to enhance growth in the sector [6] - The long-term investment advantages of gold are highlighted, with expected growth in demand due to anticipated interest rate cuts and changing consumer preferences [7] - Recent tax policy adjustments for gold are expected to accelerate industry compliance and reshape market dynamics [8] - The sports and outdoor industry is seen as a significant contributor to economic growth, with ongoing government support for high-quality development [9] - The beauty and personal care industry is transitioning from penetration expansion to quality upgrades, with a focus on domestic brands and technological advantages [10] Summary by Sections Industry Overview - The retail industry index rose by 0.31% in the week of November 3-7, 2025, ranking 17th among 31 primary industries [4] Economic Policies - The Ministry of Finance's actions aim to stimulate consumption and enhance financial cooperation with local governments [5] Consumer Trends - The CPI and core CPI show positive trends, indicating a recovery in consumer spending [5] Sector-Specific Insights - Trendy toys are experiencing rapid demand growth, with AI integration expected to drive innovation [6] - The gold and jewelry sector is poised for growth due to changing consumer preferences and favorable tax policies [7][8] - The sports and outdoor sector is benefiting from government reforms and increased consumer confidence [9] - The beauty industry is shifting towards quality and brand loyalty, with a focus on domestic products [10] Investment Recommendations - Suggested companies to watch include: - Gold and jewelry: Laopuyin, Laofengxiang, Chaohongji [11] - Trendy toys: Pop Mart, Bluc, TOPTOY, Lezitiancheng [11] - Sports and outdoor: Anta, Li Ning, 361 Degrees, Bosideng [11] - Beauty and personal care: Proya, Mao Ge Ping, Jinbo Biological, Runben, Dengkang Oral, Baiya [11]

Core Viewpoint - The collagen market is experiencing a downturn, with major brands like 可复美 and 巨子生物 showing significant declines in sales and market presence, indicating a shift from a previously thriving segment to a more cautious phase of industry consolidation and strategic realignment [1][3][4]. Market Performance - The overall performance of the collagen segment during the 2025 Double Eleven shopping festival was disappointing, with notable brands struggling to maintain their previous sales figures [3]. - Data from Citibank indicates that 巨子生物's products faced reduced price attractiveness due to stricter promotional strategies, leading to a decline in sales [4]. - 可复美's GMV on Douyin dropped to between 0.5 and 0.75 billion yuan, down from over 1 billion yuan in the same period last year, reflecting a significant contraction in market demand [4]. - The brand's ranking on Douyin's beauty list fell from the top 10 to the 20th position, highlighting a shift in consumer preferences [4]. Strategic Shifts - Major players like 巨子生物 and 锦波生物 are expanding their business boundaries, moving from consumer markets to B2B opportunities, indicating a strategic pivot in response to market changes [5][6]. - 锦波生物's revenue and net profit growth rates hit a five-year low, with its market capitalization dropping from over 500 billion yuan to 267 billion yuan [5]. - 巨子生物's stock price has seen a decline of 55.18% since reaching a peak in May, reflecting investor concerns over slowing growth and product controversies [5]. Technological Advancements - The collagen market is transitioning from a focus on cosmetic applications to medical uses, with companies investing in R&D to meet regulatory standards for medical devices [7][8]. - 华熙生物 is actively pursuing new patents related to recombinant collagen, indicating a shift towards more scientifically validated products [7][8]. - The competition is now centered around material science and clinical validation, with companies needing to demonstrate the efficacy of their products to gain market share [9]. Industry Dynamics - The narrative surrounding collagen is evolving from a marketing-driven approach to one focused on scientific and clinical validation, with companies needing to establish robust production and quality control systems [9]. - The market is no longer driven by brand recognition alone; the ability to provide clinically proven, stable, and scalable products is becoming the new competitive edge [9].

证券简称：锦波生物 证券代码：920982.BJ 山西锦波生物医药股份有限公司 （山西综改示范区太原唐槐园区锦波街 18 号） 关于山西锦波生物医药股份有限公司 向特定对象发行股票申请文件的 审核问询函之回复 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 二〇二五年十一月 北京证券交易所： 贵所于 2025 年 9 月 30 日出具的《关于山西锦波生物医药股份有限公司向特 定对象发行股票申请文件的审核问询函》（以下简称"问询函"）已收悉。山西 锦波生物医药股份有限公司（以下简称"发行人""锦波生物"或"公司"）会 同保荐人中信证券股份有限公司（以下简称"中信证券"）、中汇会计师事务所 （特殊普通合伙）（以下简称"申报会计师"或"中汇"）、上海市锦天城律师 事务所（以下简称"发行人律师"或"锦天城"）等相关方对问询函所列问题进 行了逐项核查，现回复如下，请予以审核。 除特别说明，本问询函回复所使用的简称或名词释义与《山西锦波生物医药 股份有限公司 2025 年度向特定对象发行股票募集说明书（申报稿）》中的释义 相同。若出现合计数值与各分项数值之和尾数不符的情况，均为四舍五入 ...